Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

302.85 +6.48 (+2.18%)
Streaming Delayed Price Updated: 2:33 PM EDT, May 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,019,484
Open 297.18
Bid (Size) 302.84 (1)
Ask (Size) 302.93 (2)
Prev. Close 296.37
Today's Range 295.49 - 303.57
52wk Range 218.44 - 329.72
Shares Outstanding N/A
Dividend Yield 2.81%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases. 
Via Benzinga
Exposures Product Safety
Where Will Amgen Be in 3 Years?
The Amgen of 2027 could be much be larger than some investors expect. 
Via The Motley Fool

Performance

YTD
+1.83%
+1.83%
1 Month
+10.93%
+10.93%
3 Month
+4.73%
+4.73%
6 Month
+14.08%
+14.08%
1 Year
+32.57%
+32.57%

More News

Read More
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
Via InvestorPlace
Topics ETFs
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
Via The Motley Fool
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
Via Benzinga
Exposures Product Safety
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $5,700 Today
Via Benzinga
Amgen Unusual Options Activity
Via Benzinga
Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now
Via InvestorPlace
Topics Stocks
Exposures US Equities
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Via Benzinga
Topics ETFs
7 Reliable Blue-Chip Stocks That Cannot Miss
Via InvestorPlace
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Via Benzinga
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Via InvestorPlace
Dow Jones Industrial Average Closes Above 40,000 In Quiet Friday Climb
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Via The Motley Fool
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
Via Benzinga
Topics Cannabis
Exposures Cannabis
Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?
Via InvestorPlace
FDA Gives Accelerated Approval To Amgen's Drug For Small Cell Lung Cancer Patients
Via Benzinga
Exposures Product Safety
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Via The Motley Fool
S&P 500, Nasdaq 100, Dow Jones Shatter Record Highs In Unstoppable Bull Market Rally
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
The 3 Best Dow Stocks to Buy in May 2024
Via InvestorPlace
Topics Stocks
Exposures US Equities
Amgen Is Working On a Wegovy Competitor -- What It Means for Investors
Via The Motley Fool
5 Stocks Driving Dow's Market-Beating Performance
Via Talk Markets
Topics Stocks
Exposures US Equities
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
Via InvestorPlace
Trade Desk To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Wall Street Stares At Weaker Open On Rate Anxiety, Hopes For Better Earnings: Analyst Pencils Key S&P 500 Support Level
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.